Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision tag was updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-13T17:45:10.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Revision: v3.4.1 replaces the previous v3.4.0 on the page.
    Difference
    0.1%
    Check dated 2026-02-06T11:16:28.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    New UI options Show glossary and Hide glossary were added, and a revision note at the bottom now shows Revision: v3.4.0. The terms 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' were adjusted in wording/capitalization.
    Difference
    0.4%
    Check dated 2026-01-23T04:48:46.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; this appears to be a maintenance/version update rather than changes to page content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-16T01:51:16.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Location details are reorganized: a new Locations section lists Beijing Municipality, Guangdong, Jilin, Shandong, and Sichuan as study sites; the prior separate location blocks are removed. The HHS Vulnerability Disclosure link is removed and the page revision is updated to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-18T20:40:59.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    Revision: v3.3.2 replaces v3.2.0 on the page.
    Difference
    0.1%
    Check dated 2025-11-27T04:11:33.000Z thumbnail image

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.